As of September 30, 2023, the Company had cash and cash equivalents of approximately $3.5 million. Expected GRI-0803 Upcoming Milestones: H1 2024: Complete IND-enabling studies; H1 2024: File IND and launch Phase 1a/b; Q3 2024: Report Phase 1a SAD topline results; Q4 2024: Report Phase 1b MAD topline results. “Over the course of this year, we have made fundamental progress on the development and regulatory fronts for our lead program GRI-0621 for IPF as well as GRI-083 for SLE. Importantly, we believe 2024 will be the year of data for GRI Bio,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “We believe we are positioning ourselves for a transformational year and have the potential to unlock significant value for all stakeholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRI:
- GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
- GRI Bio presents data on approach of NKT Cell Modulators at AFDD Summit
- GRI Bio presents translational data on NKT cells in patients with IPF
- GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference